Target Information
| Target General Information | Top | |||||
|---|---|---|---|---|---|---|
| Target ID |
T05034
|
|||||
| Target Name |
Fatty acid-binding protein (FABP)
|
|||||
| Synonyms |
Fatty acid binding protein
Click to Show/Hide
|
|||||
| Gene Name |
NO-GeName
|
|||||
| Target Type |
Patented-recorded target
|
[1] | ||||
| Disease | [+] 1 Target-related Diseases | + | ||||
| 1 | Obesity [ICD-11: 5B80-5B81] | |||||
| UniProt ID | ||||||
| Drugs and Modes of Action | Top | |||||
|---|---|---|---|---|---|---|
| Discontinued Drug(s) | [+] 1 Discontinued Drugs | + | ||||
| 1 | BVT-24834 | Drug Info | Terminated | Obesity | [2] | |
| Mode of Action | [+] 1 Modes of Action | + | ||||
| Inhibitor | [+] 20 Inhibitor drugs | + | ||||
| 1 | PMID27109571-Compound-1 | Drug Info | [1] | |||
| 2 | PMID27109571-Compound-2 | Drug Info | [1] | |||
| 3 | PMID27109571-Compound-3 | Drug Info | [1] | |||
| 4 | PMID27109571-Compound-32 | Drug Info | [1] | |||
| 5 | PMID27109571-Compound-33 | Drug Info | [1] | |||
| 6 | PMID27109571-Compound-34 | Drug Info | [1] | |||
| 7 | PMID27109571-Compound-35 | Drug Info | [1] | |||
| 8 | PMID27109571-Compound-36 | Drug Info | [1] | |||
| 9 | PMID27109571-Compound-37 | Drug Info | [1] | |||
| 10 | PMID27109571-Compound-38 | Drug Info | [1] | |||
| 11 | PMID27109571-Compound-39 | Drug Info | [1] | |||
| 12 | PMID27109571-Compound-4 | Drug Info | [1] | |||
| 13 | PMID27109571-Compound-40 | Drug Info | [1] | |||
| 14 | PMID27109571-Compound-41 | Drug Info | [1] | |||
| 15 | PMID27109571-Compound-42 | Drug Info | [1] | |||
| 16 | PMID27109571-Compound-43 | Drug Info | [1] | |||
| 17 | PMID27109571-Compound-44 | Drug Info | [1] | |||
| 18 | PMID27109571-Compound-5 | Drug Info | [1] | |||
| 19 | PMID27109571-Compound-6 | Drug Info | [1] | |||
| 20 | BVT-24834 | Drug Info | [3] | |||
| Drug Property Profile of Target | Top | |
|---|---|---|
| (1) Molecular Weight (mw) based Drug Clustering | (2) Octanol/Water Partition Coefficient (xlogp) based Drug Clustering | |
|
|
||
| (3) Hydrogen Bond Donor Count (hbonddonor) based Drug Clustering | (4) Hydrogen Bond Acceptor Count (hbondacc) based Drug Clustering | |
|
|
||
| (5) Rotatable Bond Count (rotbonds) based Drug Clustering | (6) Topological Polar Surface Area (polararea) based Drug Clustering | |
|
|
||
| "RO5" indicates the cutoff set by lipinski's rule of five; "D123AB" colored in GREEN denotes the no violation of any cutoff in lipinski's rule of five; "D123AB" colored in PURPLE refers to the violation of only one cutoff in lipinski's rule of five; "D123AB" colored in BLACK represents the violation of more than one cutoffs in lipinski's rule of five | ||
| References | Top | |||||
|---|---|---|---|---|---|---|
| REF 1 | Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. | |||||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021433) | |||||
| REF 3 | Fragment-Based Drug Discovery: A Practical Approach. Edward Zartler, Michael Shapiro, 2008. Page(84). | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.